Kihara James 4
4 · ACADIA PHARMACEUTICALS INC · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Accounting Officer James Kihara Sells Shares, Exercises RSUs
What Happened
James Kihara, Principal Accounting Officer of ACADIA Pharmaceuticals (ACAD), converted restricted stock units (RSUs) into common shares and sold a total of 1,942 shares in open-market transactions to cover tax withholding. The sales occurred on March 25–26, 2026 for total proceeds of approximately $41,896. The filing also records the RSU conversions (derivative exercises) on March 24–25, 2026.
Key Details
- Insider: James Kihara, Principal Accounting Officer. Filing date: 2026-03-26 (reporting period includes transactions beginning 2026-03-24). Filing appears timely.
- Sales (open market/private sale):
- 2026-03-25: 833 shares @ $21.47 = $17,885
- 2026-03-26: 1,097 shares @ $21.65 = $23,750
- 2026-03-26: 12 shares @ $21.73 = $261
- Total sold: 1,942 shares for ~$41,896
- Derivative/vesting activity:
- 2026-03-24: 1,627 RSUs converted to shares (reported as acquired)
- 2026-03-25: 2,142 RSUs converted to shares (reported as acquired)
- Additional derivative entries show conversions recorded at $0.00, indicating non-cash conversion of units to shares.
- Footnotes:
- F1: Each RSU represents a contingent right to one share.
- F2: Sales were mandatory to cover withholding taxes and intended to comply with Rule 10b5-1(c) requirements.
- F3/F4: Two RSU grants appear to have different vesting schedules (four equal annual installments beginning 3/24/2026 and 3/25/2025).
- Shares owned after the transactions are not specified in the provided filing excerpt.
Context
These transactions look like routine, tax-withholding sales tied to RSU vesting rather than discretionary insider selling for investment reasons. In plain terms: RSUs vested (converted into shares), and some of those shares were immediately sold to satisfy tax obligations — a common "sell-to-cover" practice. Such transactions generally carry less information about the insider's view of the company compared with voluntary, substantial open-market purchases.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-03-24+1,627→ 26,685 total - Sale
Common Stock
[F2]2026-03-25$21.47/sh−833$17,885→ 25,852 total - Exercise/Conversion
Common Stock
[F1]2026-03-25+2,142→ 27,994 total - Sale
Common Stock
[F2]2026-03-26$21.65/sh−1,097$23,750→ 26,897 total - Sale
Common Stock
[F2]2026-03-26$21.73/sh−12$261→ 26,885 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-03-24−1,627→ 4,883 total→ Common Stock (1,627 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-03-25−2,142→ 4,284 total→ Common Stock (2,142 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The restricted stock units vest in four equal annual installments beginning March 24, 2026.
- [F4]The restricted stock units vest in four equal annual installments beginning March 25, 2025.